Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 26, 2023; 11(36): 8603-8605
Published online Dec 26, 2023. doi: 10.12998/wjcc.v11.i36.8603
Published online Dec 26, 2023. doi: 10.12998/wjcc.v11.i36.8603
Lyophilized recombinant human brain natriuretic peptide: A promising therapy in patients with chronic heart failure
Christos Kourek, Medical School of Athens, National and Kapodistrian University of Athens, Athens 15772, Greece
Alexandros Briasoulis, Department of Clinical Therapeutics, Alexandra Hospital, Faculty of Medicine, National and Kapodistrian University of Athens, Athens 11528, Greece
Grigorios Giamouzis, John Skoularigis, Andrew Xanthopoulos, Department of Cardiology, University Hospital of Larissa, Larissa 41110, Greece
Author contributions: Kourek C conceived and designed the study, acquired the data, and analyzed and interpreted the data; Briasoulis A, Giamouzis G, Skoularigis J, and Xanthopoulos A drafted and made critical revisions to the manuscript; all authors have read and gave final approval of the version of the article to be published.
Conflict-of-interest statement: All the authors state that they have no potential or real conflicts of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Andrew Xanthopoulos, FACC, MD, PhD, Senior Postdoctoral Fellow, Department of Cardiology, University Hospital of Larissa, Mezourlo, Larissa 41110, Greece. andrewvxanth@gmail.com
Received: September 13, 2023
Peer-review started: September 13, 2023
First decision: December 5, 2023
Revised: December 5, 2023
Accepted: December 12, 2023
Article in press: December 12, 2023
Published online: December 26, 2023
Processing time: 98 Days and 23.4 Hours
Peer-review started: September 13, 2023
First decision: December 5, 2023
Revised: December 5, 2023
Accepted: December 12, 2023
Article in press: December 12, 2023
Published online: December 26, 2023
Processing time: 98 Days and 23.4 Hours
Core Tip
Core Tip: Lyophilized recombinant brain natriuretic peptide is an exogenous peptide synthesized by artificial recombination technology, with a similar structure and similar physiological effects with the endogenous natriuretic peptide secreted by the human body. A recent single center, randomized study examined its safety and efficacy in 102 chronic heart failure patients, showing promising results. Larger randomized controlled trials are urgently needed.